Alexion to present new data on ALXN1210 at EHA

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that positive results from one of the two large Phase III studies of ALXN1210, the company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for presentation during the late-breaking oral session on June 17, 2018 at the Annual Conference of the European Hematology Association (EHA) in Stockholm, Sweden.

“We are very excited about EHA’s recognition of the robustness and importance of these data in complement inhibitor treatment-naïve patients. We enrolled a very broad patient population, representative of patients with PNH in clinical practice, including patients with a history of aplastic anemia, and ‘classic’ PNH, as well as transfused and non-transfused patients,” said John Orloff, executive vice president and head of R&D at Alexion. “We look forward to discussing the data with leading hematologists in Europe at the conference later this week as part of our ambition to make ALXN1210 the new standard of care for patients with PNH.”

As previously announced, weight-optimized treatment every eight weeks with ALXN1210 demonstrated non-inferiority to treatment every two weeks with Soliris (eculizumab) in complement inhibitor treatment-naïve patients with PNH on the two co-primary endpoints and all four key secondary endpoints.